Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer
Interventions: Cabozantinib, Nivolumab; Drug
Lead sponsor: Rana McKay, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: La Jolla, California • Chicago, Illinois • Dallas, Texas + 1 more

Conditions: Prostate Cancer, Pain
Interventions: Azacitidine, Docetaxel, Prednisone, GADD45α methylation and expression analysis, Pegfilgrastim, Filgrastim; Drug · Genetic
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Prostate Cancer
Interventions: Vitamin D, Omega-3, Turmeric; Dietary Supplement
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Male only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC V7, Stage IIA Prostate Cancer AJCC v7
Interventions: Behavioral Dietary Intervention, Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration; Behavioral · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 40 Years and older · Male only
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: educational internet site on prostate cancer screening, Educational print booklet, Usual care; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 45 Years to 70 Years · Male only
Enrollment: 1,893 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Bladder Cancer
Interventions: CLSP-1025; Drug
Lead sponsor: Clasp Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 14 more

Conditions: Prostate Cancer
Interventions: MUC-2-Globo H-KLH conjugate vaccine, QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer
Interventions: MGA271; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 12
States / cities: Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more

Conditions: Prostate Cancer
Interventions: 68-Ga RM2., 68-Ga PSMA11, PET/MRI; Drug · Device
Lead sponsor: Andrei Iagaru; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prostate Adenocarcinoma, Prostate Cancer
Interventions: Transvesical Single Port Robotic Partial Prostatectomy, High-intensity focused ultrasound (HIFU); Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older · Male only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: Bicalutamide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Tumors
Interventions: IMP7068; Drug
Lead sponsor: Impact Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Atlanta, Georgia • Fairway, Kansas • Louisville, Kentucky + 4 more

Conditions: Prostatic Neoplasms
Interventions: Leuprolide Mesylate; Drug
Lead sponsor: Foresee Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: Homewood, Alabama • Laguna Hills, California • San Diego, California + 5 more

Conditions: Prostate Cancer
Interventions: 3-D Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Casodex, Zoladex , Lupron; Radiation · Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Fairway, Kansas

Conditions: Prostate Cancer
Interventions: Control, Sipuleucel-T; Other · Biological
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 18
States / cities: Berkeley, California • Laguna Hills, California • Aurora, Colorado + 13 more

Conditions: Prostate Cancer
Interventions: Erlotinib (Tarceva); Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Chicago, Illinois • Evanston, Illinois

Conditions: Prostate Cancer
Interventions: AZD6621; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Orlando, Florida • Tampa, Florida • Boston, Massachusetts + 3 more

Conditions: Prostate Cancer, Breast Cancer
Interventions: ActiveHeal; Behavioral
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Prostate Cancer
Interventions: green tea, placebo, decaffeinated black tea; Dietary Supplement
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Bipolar Radiofrequency Focal Ablation; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
Interventions: Abemaciclib, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 925 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 63
States / cities: Prescott, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 57 more

Conditions: Prostate Carcinoma
Interventions: Actigraph, Questionnaire Administration, Systematic Light Exposure; Device · Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 60 Years and older · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Duarte, California

Conditions: Prostate Cancer
Interventions: dutasteride, placebo; Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostatic Neoplasms
Interventions: 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 20
States / cities: Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more

Search by objective public record fields.

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer

Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer

Internet-Based Education for Prostate Cancer Screening

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Safety Study of MGA271 in Refractory Cancer

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer

The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients

PROvenge Treatment and Early Cancer Treatment

Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

A Trial for a Preliminary Estimate of the Effectiveness of a Novel Theoretical Framework

Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery

MRI-Targeted Focal Ablation of the Prostate in Men With Prostate Cancer

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy

Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer